Literature DB >> 32220886

Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma.

Fresia Pareja1, David N Brown1, Ju Youn Lee1, Arnaud Da Cruz Paula2, Pier Selenica1, Rui Bi1, Felipe C Geyer1, Andrea Gazzo1, Edaise M da Silva1, Mahsa Vahdatinia1, Anthe A Stylianou2, Lorenzo Ferrando1,3, Hannah Y Wen1, James B Hicks4, Britta Weigelt5, Jorge S Reis-Filho5,6.   

Abstract

PURPOSE: Ductal carcinoma in situ (DCIS) is a nonobligate precursor of invasive breast cancer. Here, we sought to investigate the level of intralesion genetic heterogeneity in DCIS and the patterns of clonal architecture changes in the progression from DCIS to invasive disease. EXPERIMENTAL
DESIGN: Synchronous DCIS (n = 27) and invasive ductal carcinomas of no special type (IDC-NSTs; n = 26) from 25 patients, and pure DCIS (n = 7) from 7 patients were microdissected separately and subjected to high-depth whole-exome (n = 56) or massively parallel sequencing targeting ≥410 key cancer-related genes (n = 4). Somatic genetic alterations, mutational signatures, clonal composition, and phylogenetic analyses were defined using validated computational methods.
RESULTS: DCIS revealed genetic alterations similar to those of synchronously diagnosed IDC-NSTs and of non-related IDC-NSTs from The Cancer Genome Atlas (TCGA), whereas pure DCIS lacked PIK3CA mutations. Clonal decomposition and phylogenetic analyses based on somatic mutations and copy number alterations revealed that the mechanisms of progression of DCIS to invasive carcinoma are diverse, and that clonal selection might have constituted the mechanism of progression from DCIS to invasive disease in 28% (7/25) of patients. DCIS displaying a pattern of clonal selection in the progression to invasive cancer harbored higher levels of intralesion genetic heterogeneity than DCIS where no clonal selection was observed.
CONCLUSIONS: Intralesion genetic heterogeneity is a common feature in DCIS synchronously diagnosed with IDC-NST. DCIS is a nonobligate precursor of IDC-NST, whose mechanisms of progression to invasive breast cancer are diverse and vary from case to case. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32220886      PMCID: PMC7367727          DOI: 10.1158/1078-0432.CCR-19-2563

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  43 in total

1.  The mathematical theory of communication. 1963.

Authors:  C E Shannon
Journal:  MD Comput       Date:  1997 Jul-Aug

2.  PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.

Authors:  Rita A Sakr; Britta Weigelt; Sarat Chandarlapaty; Victor P Andrade; Elena Guerini-Rocco; Dilip Giri; Charlotte K Y Ng; Catherine F Cowell; Neal Rosen; Jorge S Reis-Filho; Tari A King
Journal:  Clin Cancer Res       Date:  2014-03-14       Impact factor: 12.531

3.  PyClone: statistical inference of clonal population structure in cancer.

Authors:  Andrew Roth; Jaswinder Khattra; Damian Yap; Adrian Wan; Emma Laks; Justina Biele; Gavin Ha; Samuel Aparicio; Alexandre Bouchard-Côté; Sohrab P Shah
Journal:  Nat Methods       Date:  2014-03-16       Impact factor: 28.547

4.  Contralateral breast cancers: Independent cancers or metastases?

Authors:  Colin B Begg; Irina Ostrovnaya; Felipe C Geyer; Anastasios D Papanastasiou; Charlotte K Y Ng; Rita A Sakr; Jonine L Bernstein; Kathleen A Burke; Tari A King; Salvatore Piscuoglio; Audrey Mauguen; Irene Orlow; Britta Weigelt; Venkatraman E Seshan; Monica Morrow; Jorge S Reis-Filho
Journal:  Int J Cancer       Date:  2017-09-28       Impact factor: 7.396

5.  Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.

Authors:  Charlotte K Y Ng; Anne M Schultheis; Francois-Clement Bidard; Britta Weigelt; Jorge S Reis-Filho
Journal:  J Natl Cancer Inst       Date:  2015-02-23       Impact factor: 13.506

Review 6.  Progression from ductal carcinoma in situ to invasive breast cancer: revisited.

Authors:  Catherine F Cowell; Britta Weigelt; Rita A Sakr; Charlotte K Y Ng; James Hicks; Tari A King; Jorge S Reis-Filho
Journal:  Mol Oncol       Date:  2013-07-12       Impact factor: 6.603

7.  Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.

Authors:  Lucia Hernandez; Paul M Wilkerson; Maryou B Lambros; Adriana Campion-Flora; Daniel Nava Rodrigues; Arnaud Gauthier; Cecilia Cabral; Vidya Pawar; Alan Mackay; Roger A'Hern; Caterina Marchiò; Jose Palacios; Rachael Natrajan; Britta Weigelt; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2012-03-21       Impact factor: 7.996

8.  Absolute quantification of somatic DNA alterations in human cancer.

Authors:  Scott L Carter; Kristian Cibulskis; Elena Helman; Aaron McKenna; Hui Shen; Travis Zack; Peter W Laird; Robert C Onofrio; Wendy Winckler; Barbara A Weir; Rameen Beroukhim; David Pellman; Douglas A Levine; Eric S Lander; Matthew Meyerson; Gad Getz
Journal:  Nat Biotechnol       Date:  2012-05       Impact factor: 54.908

9.  Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study.

Authors:  Cathy B Moelans; Roel A de Weger; Hanneke N Monsuur; Anoek H J Maes; Paul J van Diest
Journal:  Anal Cell Pathol (Amst)       Date:  2010       Impact factor: 2.916

10.  Genome doubling shapes the evolution and prognosis of advanced cancers.

Authors:  Craig M Bielski; Ahmet Zehir; Alexander V Penson; Mark T A Donoghue; Walid Chatila; Joshua Armenia; Matthew T Chang; Alison M Schram; Philip Jonsson; Chaitanya Bandlamudi; Pedram Razavi; Gopa Iyer; Mark E Robson; Zsofia K Stadler; Nikolaus Schultz; Jose Baselga; David B Solit; David M Hyman; Michael F Berger; Barry S Taylor
Journal:  Nat Genet       Date:  2018-07-16       Impact factor: 38.330

View more
  16 in total

1.  Morphological intratumor heterogeneity in ductal carcinoma in situ of the breast.

Authors:  Claudia Stanciu-Pop; Marie-Cécile Nollevaux; Martine Berlière; Francois P Duhoux; Latifa Fellah; Christine Galant; Mieke R Van Bockstal
Journal:  Virchows Arch       Date:  2021-01-27       Impact factor: 4.064

Review 2.  Is loss of p53 a driver of ductal carcinoma in situ progression?

Authors:  Rhiannon L Morrissey; Alastair M Thompson; Guillermina Lozano
Journal:  Br J Cancer       Date:  2022-06-28       Impact factor: 7.640

Review 3.  Ductal Carcinoma in Situ: State-of-the-Art Review.

Authors:  Lars J Grimm; Habib Rahbar; Monica Abdelmalak; Allison H Hall; Marc D Ryser
Journal:  Radiology       Date:  2021-12-21       Impact factor: 11.105

4.  MUC1 expressing tumor growth was retarded after human mucin 1 (MUC1) plasmid DNA immunization.

Authors:  Hye-Youn Son; Hwan-Kyu Jeong; Vasso Apostolopoulos; Chul-Woo Kim
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.298

Review 5.  Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

Authors:  Anna K Casasent; Mathilde M Almekinders; Charlotta Mulder; Proteeti Bhattacharjee; Deborah Collyar; Alastair M Thompson; Jos Jonkers; Esther H Lips; Jacco van Rheenen; E Shelley Hwang; Serena Nik-Zainal; Nicholas E Navin; Jelle Wesseling
Journal:  Nat Rev Cancer       Date:  2022-10-19       Impact factor: 69.800

6.  Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.

Authors:  Olga T Filippova; Pier Selenica; Fresia Pareja; Mahsa Vahdatinia; Yingjie Zhu; Xin Pei; Nadeem Riaz; Kara Long Roche; Dennis S Chi; Nadeem R Abu-Rustum; Lora H Ellenson; Jorge S Reis-Filho; Dmitriy Zamarin; Britta Weigelt
Journal:  Gynecol Oncol       Date:  2021-03-03       Impact factor: 5.482

7.  Genomic Alterations during the In Situ to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System.

Authors:  Anne Trinh; Carlos R Gil Del Alcazar; Sachet A Shukla; Koei Chin; Young Hwan Chang; Guillaume Thibault; Jennifer Eng; Bojana Jovanović; C Marcelo Aldaz; So Yeon Park; Joon Jeong; Catherine Wu; Joe Gray; Kornelia Polyak
Journal:  Mol Cancer Res       Date:  2020-12-18       Impact factor: 6.333

8.  Molecular subtyping reveals uniqueness of prognosis in breast ductal carcinoma in situ patients with lumpectomy.

Authors:  Libo Yang; Mengjia Shen; Yan Qiu; Tingting Tang; Hong Bu
Journal:  Breast       Date:  2022-03-31       Impact factor: 4.254

Review 9.  Collective metastasis: coordinating the multicellular voyage.

Authors:  Emma Wrenn; Yin Huang; Kevin Cheung
Journal:  Clin Exp Metastasis       Date:  2021-07-12       Impact factor: 4.510

10.  Mutational profiling of micro-dissected pre-malignant lesions from archived specimens.

Authors:  Daniela Nachmanson; Joseph Steward; Huazhen Yao; Adam Officer; Eliza Jeong; Thomas J O'Keefe; Farnaz Hasteh; Kristen Jepsen; Gillian L Hirst; Laura J Esserman; Alexander D Borowsky; Olivier Harismendy
Journal:  BMC Med Genomics       Date:  2020-11-18       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.